Theramx has been steadily conducting collaborative research involving nano, bio, and polymer technologies verified through Korean Food and Drug Administration and European CE authority, together with advisory research fellows of leading external research institutions. Based on nano-biomaterials manufacturing technology and bio-adhesive technology, Theramx is developing a drug delivery system enabling progressive, controlled and stable drug administration through a dramatic improvement in adhesiveness, permeability, sustained release and persistence which have been identified as limitations in patch-type Drug Delivery System (DDS) of the existing pharmaceutical companies.